A Defining Milestone for Swiss Rockets and Complete Genomics

This transaction positions both organizations for accelerated global growth and technological leadership in next-generation sequencing.

Building on a Strategic Foundation

This acquisition builds upon the previously announced strategic licensing agreement between Swiss Rockets, Complete Genomics, and MGI Tech. That agreement established exclusive rights to key sequencing intellectual property, including CoolMPS chemistry, and created the operational framework for technology transfer and long-term collaboration.

Today’s definitive agreement represents the natural next step: full integration of the platform to scale innovation, diversify manufacturing capacity, and strengthen operational independence.

Strategic Rationale

Complete Genomics brings more than two decades of innovation in next-generation sequencing and advanced chemistries. Its technology platform complements Swiss Rockets’ long-term vision in oncology, immunology, and precision medicine.

By integrating genomic sequencing capabilities directly into our group structure, Swiss Rockets strengthens its ability to:

• Expand access to precision medicine and preventive health
• Accelerate development of next-generation diagnostics
• Enable data-driven therapeutic innovation
• Build resilient, diversified manufacturing and supply chains

This step significantly advances our mission of making high-quality genome sequencing accessible at global scale.

What This Means for Customers and Partners

Customers can expect full continuity across products, services, software, data handling practices, and support.

Complete Genomics will continue to operate as a U.S.-based company. Its management team will retain responsibility for day-to-day operations, product strategy, software development, and customer relationships.

All software and systems will continue to be developed and maintained by the U.S.-based team.

An Extraordinary Team Effort

This milestone reflects an exceptional level of dedication and collaboration across multiple teams and jurisdictions. The agreements include:

• A Share Purchase Agreement for 100% acquisition
• An expanded Exclusive License Agreement covering CoolMPS and StandardMPS technologies
• A Development and Supply Agreement

The transaction has already received approval from Chinese authorities. Remaining approvals – including Chinese shareholder and U.S. regulatory approvals – are expected in the coming months.

The official public announcement will take place at the AGBT Conference in Orlando, one of the world’s leading genome conferences.

A Transformational Step for Swiss Rockets

The integration of Complete Genomics – a commercial platform backed by substantial historical R&D investment – significantly strengthens the long-term value proposition of our group.

This acquisition does not mark the end of a journey. It marks the beginning of a new phase.

We believe genomic infrastructure will define the next decade of precision medicine. With Complete Genomics fully integrated, Swiss Rockets is uniquely positioned at the intersection of sequencing, therapeutics, and molecular health.

For those who share our long-term vision, opportunities to participate in this next growth chapter remain available. We welcome conversations with partners who wish to be part of this transformation.

Looking Ahead

This is more than a transaction.
It is a structural shift.
It is the foundation for global impact.
We thank all partners, team members, and supporters who contributed to reaching this milestone.
The journey continues – and the opportunity is substantial.

With respect and confidence,
Dr. Vladimir Cmiljanovic
Founder & CEO
Swiss Rockets AG